Literature DB >> 16751791

Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock.

Oliver Murch1, Marika Collin, Bruno Sepodes, Simon J Foster, Helder Mota-Filipe, Christoph Thiemermann.   

Abstract

1. Lysophosphatidylcholine (LPC) modulates the inflammatory response and reduces mortality in animal models of sepsis. Here, we investigate the effects of LPC from synthetic (sLPC) and natural, soy bean derived LPC, (nLPC) sources on the organ injury/dysfunction caused by systemic administration of lipopolysaccharide (LPS) or peptidoglycan (PepG) and lipoteichoic acid (LTA). 2. Rats were subjected to (i) endotoxaemia (LPS 6 mg kg(-1) i.v.) and treated with sLPC (1-100 mg kg(-1)), (ii) endotoxaemia and treated with nLPC (10 mg kg(-1)) or (iii) gram-positive shock (PepG 10 mg kg(-1) and LTA 3 mg kg(-1) i.v.) and treated with sLPC (10 mg kg(-1)). 3. Endotoxaemia or gram-positive shock for 6 h resulted in increases in serum makers of renal dysfunction and liver, pancreatic and neuromuscular injury. 4. Administration of sLPC, at 1 or 2 h after LPS, dose dependently (1-10 mg kg(-1)) reduced the organ injury/dysfunction. High doses of sLPC (30 and 100 mg kg(-1)) were shown to be detrimental in endotoxaemia. sLPC also afforded protection against the organ injury/dysfunction caused by gram-positive shock. nLPC was found to be protective in endotoxaemic animals. 5. The beneficial effects of sLPC were associated with an attenuation in circulating levels of interleukin-1beta (IL-1beta). 6. In conclusion, LPC dose and time dependently reduces the organ injury and circulating IL-1beta levels caused by gram-negative or gram-positive shock in the rat. Thus, we speculate that appropriate doses of LPC may be useful in reducing the degree of organ injury and dysfunction associated with shock of various aetiologies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751791      PMCID: PMC1617069          DOI: 10.1038/sj.bjp.0706788

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques.

Authors:  Yoshiyuki Rikitake; Ken-ichi Hirata; Tomoya Yamashita; Kenji Iwai; Seiichi Kobayashi; Hiroshi Itoh; Masanori Ozaki; Junya Ejiri; Masashi Shiomi; Nobutaka Inoue; Seinosuke Kawashima; Mitsuhiro Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

2.  GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat.

Authors:  Laura Dugo; Marika Collin; David A Allen; Nimesh S A Patel; Inge Bauer; Eero M A Mervaala; Marjut Louhelainen; Simon J Foster; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  Crit Care Med       Date:  2005-09       Impact factor: 7.598

3.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

4.  Effects of perfusion pressure on tissue perfusion in septic shock.

Authors:  D LeDoux; M E Astiz; C M Carpati; E C Rackow
Journal:  Crit Care Med       Date:  2000-08       Impact factor: 7.598

5.  Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2.

Authors:  Kimberly A Walton; Amy L Cole; Michael Yeh; Ganesamoorthy Subbanagounder; Stephan R Krutzik; Robert L Modlin; Robert M Lucas; Junko Nakai; Eric J Smart; Deven K Vora; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-29       Impact factor: 8.311

6.  Carboxy-PTIO, a scavenger of nitric oxide, selectively inhibits the increase in medullary perfusion and improves renal function in endotoxemia.

Authors:  Colin G M Millar; Christoph Thiemermann
Journal:  Shock       Date:  2002-07       Impact factor: 3.454

7.  Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat.

Authors:  Jacob E Wang; Maria K Dahle; Arne Yndestad; Inge Bauer; Michelle C McDonald; Pål Aukrust; Simon J Foster; Michael Bauer; Ansgar O Aasen; Christoph Thiemermann
Journal:  Crit Care Med       Date:  2004-02       Impact factor: 7.598

8.  The action mode of lysophosphatidylcholine in human monocytes.

Authors:  Mi-Ran Yun; Fumikazu Okajima; Dong-Soon Im
Journal:  J Pharmacol Sci       Date:  2004-01       Impact factor: 3.337

9.  Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients.

Authors:  Wolfgang Drobnik; Gerhard Liebisch; Franz-Xaver Audebert; Dieter Frohlich; Thomas Gluck; Peter Vogel; Gregor Rothe; Gerd Schmitz
Journal:  J Lipid Res       Date:  2003-01-16       Impact factor: 5.922

10.  Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock.

Authors:  Michelle C McDonald; Pal Dhadly; Gillian W Cockerill; Salvatore Cuzzocrea; Helder Mota-Filipe; Charles J Hinds; Norman E Miller; Christoph Thiemermann
Journal:  Shock       Date:  2003-12       Impact factor: 3.454

View more
  14 in total

1.  Monitoring mmp-9 gene expression in stromal cells using a novel transgenic mouse model.

Authors:  Katherine Biron-Pain; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2011-08-11       Impact factor: 9.261

2.  Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease.

Authors:  Igor Maricic; Enrico Girardi; Dirk M Zajonc; Vipin Kumar
Journal:  J Immunol       Date:  2014-09-26       Impact factor: 5.422

3.  Immune Response Resetting in Ongoing Sepsis.

Authors:  Alexandre E Nowill; Márcia C Fornazin; Maria C Spago; Vicente Dorgan Neto; Vitória R P Pinheiro; Simônia S S Alexandre; Edgar O Moraes; Gustavo H M F Souza; Marcos N Eberlin; Lygia A Marques; Eduardo C Meurer; Gilberto C Franchi; Pedro O de Campos-Lima
Journal:  J Immunol       Date:  2019-07-29       Impact factor: 5.422

4.  Antimicrobial effects of lysophosphatidylcholine on methicillin-resistant Staphylococcus aureus.

Authors:  Haruko Miyazaki; Naoko Midorikawa; Saki Fujimoto; Natsumi Miyoshi; Hideto Yoshida; Tetsuya Matsumoto
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

Review 5.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

6.  Response and recovery in the plasma metabolome tracks the acute LCMV-induced immune response.

Authors:  William R Wikoff; Ewa Kalisak; Sunia Trauger; Marianne Manchester; Gary Siuzdak
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

7.  Stearoyl Lysophosphatidylcholine Inhibits Endotoxin-Induced Caspase-11 Activation.

Authors:  Wenbo Li; Wei Zhang; Meihong Deng; Patricia Loughran; Yiting Tang; Hong Liao; Xianying Zhang; Jian Liu; Timothy R Billiar; Ben Lu
Journal:  Shock       Date:  2018-09       Impact factor: 3.454

8.  Identification of lysophosphatidylcholine-chlorohydrin in human atherosclerotic lesions.

Authors:  M C Messner; C J Albert; J McHowat; D A Ford
Journal:  Lipids       Date:  2008-02-07       Impact factor: 1.880

9.  Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties.

Authors:  Timothy J Cunningham; Lihua Yao; Angel Lucena
Journal:  J Inflamm (Lond)       Date:  2008-10-22       Impact factor: 4.981

10.  Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation.

Authors:  Alan Brito Carneiro; Bruna Maria Ferreira Iaciura; Lilian Lie Nohara; Carla Duque Lopes; Esteban Mauricio Cordero Veas; Vania Sammartino Mariano; Patricia Torres Bozza; Ulisses Gazos Lopes; Georgia Correa Atella; Igor Correia Almeida; Mário Alberto Cardoso Silva-Neto
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.